Terminology and products
Conditioned medium is the liquid collected after cells are grown in culture. Exosomes are a type of small particle released by cells. The same name does not guarantee the same ingredients, manufacturing process or quality controls.
Names used in the product materials
The product materials bearing the clinic's name list PureHGF×30＋Exo and PREMIUM PureHGF×125＋Exo separately. They list HGF contents of 120,000 pg and 500,000 pg per 1 vial, respectively. Both are described as freeze-dried products made from 2 mL of stock solution. These figures describe the ingredients in the materials. They do not indicate the volume infused or the magnitude of any treatment effect.
Infusion method and approximate visit schedule
The clinic's infusion materials give an approximate schedule of once every 3–4 weeks for secretome and exosome infusions. The product materials show other schedules, so there is no single interval or session count for everyone. The product, amount and interval are adjusted according to your health and assessment.
Eligibility and what to check before visiting
The clinic's consent form excludes people with a history of cancer, those who are pregnant or may be pregnant, those who are breastfeeding, and anyone the physician considers unsuitable. The clinic's self-pay care also excludes minors. Tell us about medical history, medications and allergies in advance. These conditions apply to conditioned medium treatment and are separate from those for NK-cell therapy and other treatments.
What to discuss during consultation
Discuss the purpose, the product's source and manufacturer, the method of administration, approval status in Japan, controls for infection and other quality risks, and evidence from studies in people.
Expectations and uncertainty
We cannot guarantee prevention of dementia, improvement of illness or cosmetic effects. Do not use this treatment in place of your current care or standard treatment.
Risks and research on conditioned medium and exosomes
General risks include contamination with infectious agents or impurities, unexpected immune reactions and failing to achieve the hoped-for effect. Risks depend on the cell source, manufacturing and storage controls, and the route and number of administrations. Quality testing may not detect every risk. These are general considerations and do not establish the incidence of side effects for the product used at the clinic.
When reading a study, check whether it involved cells, animals or people and whether the product, condition and route of administration match. Results for one product or method cannot automatically establish effectiveness for another treatment. Terms such as “high concentration” or “exosome-rich” do not establish effectiveness or safety.
In July 2024, Japan's Ministry of Health, Labour and Welfare drew attention to safety, quality and risk management in care using conditioned medium, exosomes and related products. Discussion materials from October 2026 also identify effectiveness, safety and determining what is actually administered as issues. The discussion materials do not indicate that new regulations have already taken effect.
Scroll the table horizontally to view all columns.
| Term | What it refers to | What the name alone cannot tell you |
|---|---|---|
| Stem cells | The cells themselves | The type and source of cells and how they are used |
| Conditioned medium | The liquid collected after cells are grown in culture | Ingredients, preparation and the quality of each product |
| Exosomes | A type of extracellular vesicle | Identification method, content and purity, and effectiveness in people |
The table explains general terminology. It does not list products or services provided by the clinic.
Precautions and risks
The clinic's consent form describes pain, bleeding, swelling, bruising, infection and associated fever after injections and similar procedures. Tell the physician or staff promptly if you have concerning symptoms during or after an infusion. Contamination with infectious agents or impurities and unexpected immune reactions are also possible concerns. Risks vary by product and route of administration. High-concentration claims and studies of other products cannot establish effectiveness or safety. Ask for an explanation specific to the actual product and infusion before proceeding.
This is an overview. Please consider a treatment or test after receiving an explanation specific to your care.
Fees and conditions
- Secretome + Exosome Rich, 1 vial
- ¥55,000 (including tax)
- Secretome + Exosome Rich, 2 vials per session × 10 sessions
- ¥1,001,000 (including tax)
- Secretome + Exosome Rich, 3 vials per session × 10 sessions
- ¥1,435,500 (including tax)
- Secretome + Exosome Rich 125, 1 vial
- ¥220,000 (including tax)
- 125 for patients with an active course agreement, 1 vial
- ¥209,000 (including tax)
- 125, 1 vial per session × 8 sessions
- ¥1,443,200 (including tax)
- 125, 1 vial per session × 10 sessions
- ¥1,782,000 (including tax)
- 125, 2 vials per session × 8 sessions
- ¥2,868,800 (including tax)
- 125, 2 vials per session × 10 sessions
- ¥3,542,000 (including tax)
- 125, 3 vials per session × 10 sessions
- ¥5,280,000 (including tax)
The clinic fee list received on 29 October 2026 gives prices plus tax. The figures shown include 10% consumption tax. Fees for the product without the 125 designation are separate from those for 125. A vial is a container unit and does not indicate the amount of active ingredient. The unit price for an active course agreement applies only to eligible patients. Confirm the conditions, any additional costs such as the initial consultation, and the administration method and interval before treatment.
What to check before your consultation
- Which product is used and for what purpose?
- What evidence is there about effectiveness and safety in people?
- How are adverse events managed?
Write down your questions and bring them with your medication record and previous test results.
How to ask about this serviceReference information
- Ministry of Health, Labour and Welfare notice on stem cell-conditioned medium, exosomes and related products (July 2024)
- Japanese Society for Regenerative Medicine guidance on clinical use of extracellular vesicles and related products, 1st edition
- Ministry of Health, Labour and Welfare notice of 31 July 2024 on stem cell-conditioned medium and exosomes
- Ministry of Health, Labour and Welfare Working Group Material 2, 8 October 2026
The explanation and its comparison with primary sources were updated on 29 October 2026. This is an overview of quality, risks and research. Product specifications and the clinic's administration conditions are separate.